CN110448719B - 一种促进凝血的丝素-多肽电纺膜及其制备方法 - Google Patents
一种促进凝血的丝素-多肽电纺膜及其制备方法 Download PDFInfo
- Publication number
- CN110448719B CN110448719B CN201910572186.0A CN201910572186A CN110448719B CN 110448719 B CN110448719 B CN 110448719B CN 201910572186 A CN201910572186 A CN 201910572186A CN 110448719 B CN110448719 B CN 110448719B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- fibroin
- electrospun membrane
- blood coagulation
- promoting blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 67
- 239000012528 membrane Substances 0.000 title claims abstract description 54
- 230000023555 blood coagulation Effects 0.000 title claims abstract description 31
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 38
- 108010022355 Fibroins Proteins 0.000 claims abstract description 31
- 241000255789 Bombyx mori Species 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 21
- 239000008176 lyophilized powder Substances 0.000 claims description 14
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 8
- 238000010041 electrostatic spinning Methods 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002121 nanofiber Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 abstract description 17
- 229940106780 human fibrinogen Drugs 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 102000009123 Fibrin Human genes 0.000 abstract description 5
- 108010073385 Fibrin Proteins 0.000 abstract description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract description 5
- 229950003499 fibrin Drugs 0.000 abstract description 5
- 238000004108 freeze drying Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 229910010272 inorganic material Inorganic materials 0.000 abstract description 2
- 239000011147 inorganic material Substances 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002861 polymer material Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 108010064995 silkworm fibroin Proteins 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000001523 electrospinning Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 1
- UROVZOUMHNXPLZ-AVGNSLFASA-N His-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 UROVZOUMHNXPLZ-AVGNSLFASA-N 0.000 description 1
- FNGOXVQBBCMFKV-CIUDSAMLSA-N Pro-Ser-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O FNGOXVQBBCMFKV-CIUDSAMLSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010017446 glycyl-prolyl-arginyl-proline Proteins 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Artificial Filaments (AREA)
Abstract
本发明公开了一种促进凝血的丝素‑多肽电纺膜及其制备方法,以家蚕丝素蛋白为载体,添加多肽GPRPPSEHLQIT制成的电纺膜,主要用于促进凝血,是一种可以靶向结合人纤维蛋白原的凝血材料,包括将蚕茧脱胶后溶解、过滤、透析、浓缩、冻干,获得丝素冻干粉等步骤,本发明中使用的多肽为自行筛选得到的多肽,对比其余多肽,可以特异性靶向结合人纤维蛋白原,该多肽通过在电纺膜上富集人纤维蛋白原,有利于在膜表面形成纤维蛋白网状结构,促进凝血,该电纺膜所使用的丝素为天然高分子蛋白,对比其余无机材料或人工合成高分子材料,生物相容性更好,安全性更高,且制作方便,便于量产。
Description
技术领域
本发明涉及凝血材料领域,具体地说,是一种促进凝血的丝素-多肽电纺膜及其制备方法。
背景技术
凝血材料的研究与应用一直是医学研究的重要领域。无论是日常生活,临床手术甚至战争等造成的创伤流血,促凝血材料的应用对于快速止血、挽救生命等具有重要意义。而血液凝固的本质便是血液中纤维蛋白原变成纤维蛋白的过程,纤维蛋白原作为凝血因子I,对凝血功能起到了巨大的作用,因此,具有能够靶向结合纤维蛋白原能力的凝血材料可以高度富集人纤维蛋白原,有利于创伤部位纤维蛋白网状结构的形成,进一步促进凝血。
家蚕丝素蛋白作为一种天然高分子蛋白,具有极好的生物相容性、可降解性、易于加工成型和良好的力学性能等优点,常被加工成为膜、凝胶、支架等材料用于再生医学等领域。多肽GPRPPSEHLQIT(SED ID NO:1)能够靶向结合人纤维蛋白原,加入凝血材料中可以使人纤维蛋白原富集在材料表面,进而促进凝血。相对于噬菌体等展示该段序列的材料,多肽的纯度更高,能够更大程度地在材料表面富集人纤维蛋白原,而且多肽的安全性、生物相容性都更优秀,更适合用于生物材料。静电纺丝技术制备的电纺膜具有纳米纤维结构,且具有更大的比表面积以及更大的孔隙率,其结构特征与许多天然组织器官相似,由丝素制成的电纺膜常被用做生物材料。丝素电纺膜的粗糙表面结构对比其余表面光滑的凝血材料,在血液流动状态下对蛋白有更好的黏附力,利于在伤口处形成血栓,促进血液凝固,伤口愈合。但传统的丝素电纺膜只能通过表面的静电吸附等作用黏附蛋白,不能靶向地结合蛋白,而人纤维蛋白原作为能显著影响凝血能力的蛋白,为了能在材料表面靶向地结合人纤维蛋白原,我们添加了能够靶向结合人纤维蛋白原的多肽GPRPPSEHLQIT(SED ID NO:1),制成了丝素-多肽电纺膜。该电纺膜可以在表面靶向地结合血液中的人纤维蛋白原,有利于在材料表面形成纤维蛋白网络状结构,促进伤口凝血。
发明内容
本发明针对传统凝血材料领域的不足,提供了一种可以靶向结合人纤维蛋白原的丝素-多肽电纺膜及其制备方法。本发明为以家蚕丝素蛋白为载体,添加多肽GPRPPSEHLQIT(SED ID NO:1)制成的电纺膜,对比传统的凝血材料以及纯丝素电纺膜的凝血效果要更佳。本发明制备的丝素-多肽电纺膜主要用于促进凝血,是一种可以靶向结合人纤维蛋白原的凝血材料。本发明的具体技术方案如下:
本发明公开了一种促进凝血的丝素-多肽电纺膜,所使用的多肽序列为GPRPPSEHLQIT(SED ID NO:1),多肽浓度为0.2mg/mL——10mg/mL。
作为进一步地改进,本发明所述的电纺膜为丝素纳米纤维交织而成,多肽均匀分布在纳米纤维中。
本发明还公开了一种促进凝血的丝素-多肽电纺膜的制备方法,所采用的具体制备步骤如下:
1)将蚕茧脱胶后溶解、过滤、透析、浓缩、冻干,获得丝素冻干粉;
2)将丝素冻干粉、多肽GPRPPSEHLQIT(SED ID NO:1)与六氟异丙醇溶液混合均匀;
3)将步骤2)所得混合溶液进行静电纺丝,即得到丝素-多肽电纺膜。
作为进一步地改进,本发明所述的步骤2)使用的丝素冻干粉:六氟异丙醇溶液的质量比为2:98——20:80。
作为进一步地改进,本发明所述的步骤2)添加的多肽GPRPPSEHLQIT(SED ID NO:1)浓度为0.2mg/mL——10mg/mL。
作为进一步地改进,本发明所述的步骤3)制备所得丝素-多肽电纺膜经过醇类处理,得到不溶于水的丝素-多肽电纺膜。
与现有技术相比,本发明具有以下突出特点:
(1)本发明中使用的多肽为自行筛选得到的多肽,对比其余多肽,可以特异性靶向结合人纤维蛋白原,该多肽通过在电纺膜上富集人纤维蛋白原,有利于在膜表面形成纤维蛋白网状结构,促进凝血;
(2)该电纺膜所使用的多肽,与表达该段多肽序列的噬菌体相比,生物安全性更高;
(3)该电纺膜所使用的丝素为天然高分子蛋白,对比其余无机材料或人工合成高分子材料,生物相容性更好,安全性更高,且制作方便,便于量产。
附图说明
图1是丝素-多肽电纺膜的电镜图。
图2是添加不同质量多肽(P,peptide)的丝素-多肽电纺膜与单纯的丝素电纺膜的活化部分凝血活酶时间(APTT,activated partial thromboplastin time)结果图。
图3是添加多肽GPRPPSEHLQIT(SED ID NO:1)与添加不同序列多肽的电纺膜的凝血指数结果图。
具体实施方式
下面通过具体实施例对本发明的技术方案作进一步的详细说明,以下实施例是对本发明的解释而本发明并不局限于以下实施例。
实施例1
(1)将蚕茧脱胶后溶解、过滤、透析、浓缩得到丝素溶液,再经冻干获得丝素冻干粉;
(2)将2g丝素冻干粉与8g六氟异丙醇溶液混合,取1mL该混合液加入10mg多肽GPRPPSEHLQIT(SED ID NO:1),得到步骤2)所得溶液;
(3)将步骤2)所得溶液进行静电纺丝,即得到丝素-多肽电纺膜,将该电纺膜进行扫描电镜的观察,可得到图1。
实施例2
(1)将蚕茧脱胶后溶解、过滤、透析、浓缩得到丝素溶液,再经冻干获得丝素冻干粉;
(2)将1g丝素冻干粉与13.29g六氟异丙醇溶液混合,分别取1mL该混合液加入0、0.2、0.4、0.6、1mg多肽GPRPPSEHLQIT(SED ID NO:1),得到步骤2)所得溶液;
(3)将步骤2)所得溶液分别进行静电纺丝,即得到丝素-多肽电纺膜;
(4)将这些电纺膜进行活化部分凝血活酶时间(APTT,activated partialthromboplastin time)检测,可得到图2的结果,说明随着多肽浓度上升,所需时间会变短,表示多肽浓度越高,凝血效果越好。
实施例3
(1)将蚕茧脱胶后溶解、过滤、透析、浓缩得到丝素溶液,再经冻干获得丝素冻干粉;
(2)将0.2g丝素冻干粉与9.8g六氟异丙醇溶液混合,分别取1mL该混合液加入0.2mg多肽GPRPPSEHLQIT(SED ID NO:1),另取1mL该混合液加入0.2mg别的多肽用于对照,得到步骤2)所得溶液;
(3)将步骤2)所得溶液分别进行静电纺丝,即得到丝素-多肽电纺膜;
(4)将上述电纺膜与新鲜血液混合分别在37℃孵育0.5、1、2、3、4min,取出凝血块后,检测未凝血液中的血红蛋白含量,占凝血前总血红蛋白含量的比例,为凝血指数BCI,可得图3,指数下降越快,表示凝血速度越快,说明加入多肽GPRPPSEHLQIT(SED ID NO:1)的电纺膜比加入别的多肽的电纺膜促凝血效果更好。
实施例4
(1)将蚕茧脱胶后溶解、过滤、透析、浓缩得到丝素溶液,再经冻干获得丝素冻干粉;
(2)将1g丝素冻干粉与9g六氟异丙醇溶液混合,取1mL该混合液加入5mg多肽GPRPPSEHLQIT(SED ID NO:1),得到步骤2)所得溶液;
(3)将步骤2)所得溶液进行静电纺丝,即得到丝素-多肽电纺膜;
(4)将步骤3)得到的电纺膜浸泡在90%乙醇中30min,得到不溶于水的丝素-多肽电纺膜。
最后,还需要注意的是,以上列举的仅是本发明的具体实施例子。显然,本发明不限于以上实施例子,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
序列表
<110> 浙江大学
<120> 一种促进凝血的丝素-多肽电纺膜及其制备方法
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 12
<212> PRT
<213> 人工序列(未知)
<400> 1
Gly Pro Arg Pro Pro Ser Glu His Leu Gln Ile Thr
1 5 10
Claims (6)
1.一种促进凝血的丝素-多肽电纺膜,其特征在于,所使用的多肽序列为GPRPPSEHLQIT(SED ID NO:1),多肽浓度为0.2mg/mL——10mg/mL。
2.根据权利要求1所述丝素-多肽电纺膜,其特征在于,所述的电纺膜为丝素纳米纤维交织而成,多肽均匀分布在纳米纤维中。
3.一种如权利要求1或2所述的促进凝血的丝素-多肽电纺膜的制备方法,其特征在于,所采用的具体制备步骤如下:
1)将蚕茧脱胶后溶解、过滤、透析、浓缩、冻干,获得丝素冻干粉;
2)将丝素冻干粉、多肽GPRPPSEHLQIT(SED ID NO:1)与六氟异丙醇溶液混合均匀;
3)将步骤2)所得混合溶液进行静电纺丝,即得到丝素-多肽电纺膜。
4.根据权利要求3所述的丝素-多肽电纺膜的制备方法,其特征在于,所述的步骤2)使用的丝素冻干粉:六氟异丙醇溶液的质量比为2:98——20:80。
5.根据权利要求3或4所述的丝素-多肽电纺膜的制备方法,其特征在于,所述的步骤2)添加的多肽GPRPPSEHLQIT(SED ID NO:1)浓度为0.2mg/mL——10mg/mL。
6.根据权利要求3所述的丝素-多肽电纺膜的制备方法,其特征在于,所述的步骤3)制备所得丝素-多肽电纺膜经过醇类处理,得到不溶于水的丝素-多肽电纺膜。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910572186.0A CN110448719B (zh) | 2019-06-28 | 2019-06-28 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
PCT/CN2020/098423 WO2020259672A1 (zh) | 2019-06-28 | 2020-06-28 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
US17/542,473 US20220088266A1 (en) | 2019-06-28 | 2021-12-05 | Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910572186.0A CN110448719B (zh) | 2019-06-28 | 2019-06-28 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110448719A CN110448719A (zh) | 2019-11-15 |
CN110448719B true CN110448719B (zh) | 2020-05-22 |
Family
ID=68481824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910572186.0A Active CN110448719B (zh) | 2019-06-28 | 2019-06-28 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220088266A1 (zh) |
CN (1) | CN110448719B (zh) |
WO (1) | WO2020259672A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110448719B (zh) * | 2019-06-28 | 2020-05-22 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
CN115721768A (zh) * | 2022-12-01 | 2023-03-03 | 国纳之星(上海)纳米科技发展有限公司 | 一种抗炎丝素蛋白膜的制备方法及其产品和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19740310A1 (de) * | 1997-09-13 | 1999-04-01 | Octapharma Ag | Peptid mit Affinität zu Gerinnungsfaktor VIII |
JP2005521733A (ja) * | 2002-03-26 | 2005-07-21 | ダイアックス、コープ | フィブリノーゲン結合部分 |
GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
JP2012533354A (ja) * | 2009-07-14 | 2012-12-27 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | 創傷治癒のための電界紡糸絹材料システム |
US9399764B2 (en) * | 2010-11-24 | 2016-07-26 | Novartis International Pharmaceutical, Ltd. | Fusion enzymes |
US9149511B2 (en) * | 2011-06-30 | 2015-10-06 | Ethicon, Inc. | Procoagulant peptides and their derivatives and uses therefor |
GB201201751D0 (en) * | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
CN103272267A (zh) * | 2013-06-07 | 2013-09-04 | 浙江大学 | 一种丝素蛋白与纳米Fe3O4复合材料的制备方法 |
GB201400292D0 (en) * | 2014-01-08 | 2014-02-26 | Haemostatix Ltd | Peptide dendrimers and agents |
GB201518466D0 (en) * | 2015-10-19 | 2015-12-02 | Cizzle Biotechnology Ltd | Use |
US20190275196A1 (en) * | 2016-06-01 | 2019-09-12 | Eun Seok Gil | Hemostatic Powders with Self-Assembling Peptide Hydrogels |
CN106636068B (zh) * | 2016-12-28 | 2019-06-07 | 浙江大学 | 一种丝素亲和肽的筛选方法 |
CN107158455A (zh) * | 2017-04-26 | 2017-09-15 | 浙江大学 | 一种噬菌体止血剂的制备方法及其应用 |
CN107137757A (zh) * | 2017-04-26 | 2017-09-08 | 浙江大学 | 一种rgd噬菌体/丝素复合止血材料及其制备方法 |
CN107899075A (zh) * | 2017-10-20 | 2018-04-13 | 浙江大学 | 一种基于特异性相互作用的自组装水凝胶及其制备方法 |
CN109157672B (zh) * | 2018-08-16 | 2020-06-23 | 浙江大学 | 一种丝素-短肽凝血微球的制备方法 |
CN110448719B (zh) * | 2019-06-28 | 2020-05-22 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
-
2019
- 2019-06-28 CN CN201910572186.0A patent/CN110448719B/zh active Active
-
2020
- 2020-06-28 WO PCT/CN2020/098423 patent/WO2020259672A1/zh active Application Filing
-
2021
- 2021-12-05 US US17/542,473 patent/US20220088266A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020259672A1 (zh) | 2020-12-30 |
CN110448719A (zh) | 2019-11-15 |
US20220088266A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Bacterial cellulose–hyaluronan nanocomposite biomaterials as wound dressings for severe skin injury repair | |
Wang et al. | Fabrication of the FGF1-functionalized sericin hydrogels with cell proliferation activity for biomedical application using genetically engineered Bombyx mori (B. mori) silk | |
Sun et al. | Effects of cross-linking on mechanical, biological properties and biodegradation behavior of Nile tilapia skin collagen sponge as a biomedical material | |
EP3112396A1 (en) | Preparation method and use of sericin hydrogel | |
US20220088266A1 (en) | Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof | |
CN106913900B (zh) | 丝素蛋白止血材料及其制备方法 | |
CN103993424A (zh) | 一种聚氨酯-角蛋白复合纳米纤维膜的制备方法 | |
Liu et al. | Dual-factor loaded functional silk fibroin scaffolds for peripheral nerve regeneration with the aid of neovascularization | |
JP2006257013A (ja) | 魚鱗由来コラーゲンゲルとその作成方法 | |
CN102133432B (zh) | 一种丝素蛋白微孔支架的制备方法 | |
JP2001524619A (ja) | タンパク質繊維の製造法とその製品 | |
Hosseini Ravandi et al. | Application of electrospun natural biopolymer nanofibers | |
CN111188194B (zh) | 一种丝素蛋白/明胶纤维增强壳聚糖复合止血材料的制备方法 | |
Yu et al. | Repair of skin defects with electrospun collagen/chitosan and fibroin/chitosan compound nanofiber scaffolds compared with gauze dressing | |
CN108822335A (zh) | 一种复合膜及其制备方法和应用 | |
CN110028685B (zh) | 一种丝素/壳聚糖/多孔氧化石墨烯复合三维支架的制备方法 | |
CN103993425A (zh) | 一种聚己内酯-角蛋白复合纳米纤维膜的制备方法 | |
CN1197631C (zh) | 一种含有表皮生长因子的皮肤组织工程支架的构建方法 | |
CN115137881A (zh) | 抗血栓、促组织再生的三层仿生人工血管及其制备方法 | |
Yuan et al. | Bioabsorbable poly (4-hydroxybutyrate)(P4HB) fibrous membranes as a potential dermal substitute | |
Hu et al. | Production of novel elastic bacterial nanocellulose/polyvinyl alcohol conduits via mercerization and phase separation for small-caliber vascular grafts application | |
CN114149610A (zh) | 一种氧化白芨改性胶原纤维制备止血海绵的方法 | |
Wang et al. | Proteomic analysis of silk fibroin reveals diverse biological function of different degumming processing from different origin | |
CN107137757A (zh) | 一种rgd噬菌体/丝素复合止血材料及其制备方法 | |
CN109157672B (zh) | 一种丝素-短肽凝血微球的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |